BIOTECH ASSISTANT / FIELD NOTES

Arvinas prioritizes European and UK development of ARV-102 for PSP

Company / institutional announcement · Arvinas

Source published: 2026-11-03

Site published: 2026-11-03 · Updated: 2026-11-03

Explore this article with AI

This source is linked automatically. Choose a question to get started.

Ask AI ↗

Findings and limitations Industry implications Related developments

What changed

Arvinas said it will prioritize a Phase 1b study of its LRRK2 degrader ARV-102 in progressive supranuclear palsy in the European Union and United Kingdom. Trial applications and regulatory authorization remain pending. The company continues discussions with US and Japanese regulators, while the US investigational new drug application remains on hold.

Why it may matter

The regional strategy could preserve development momentum, but regulatory clearance and meaningful patient outcomes remain essential tests for neurological protein degradation.

The interpretation above is analysis, not a conclusion attributed to the original source.

Read the original source ↗

Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections

Protein degradation / PROTAC

Follow the evidence

Companies mentionedArvinas ↗

Explore field companies →Explore literature →

Related updates

2026-11-06Nature Materials

In situ CAR engineering and nanoparticle-mediated TREM2 degradation for macrophage reprogramming in malignant ascites

A Nature Materials study describes mRNA-loaded LNPs that reprogram tumor-associated macrophages into Claudin18.2-targeting CAR macrophages. The lipid formulation also promotes TREM2 internalization and degradation, reshaping immune responses. The original abstract reports tumor suppression and longer survival with PD-1 blockade in mice, plus ex vivo patient-sample findings. These findings do not demonstrate clinical efficacy in treated patients.

mRNA / LNP In Vivo Cell Engineering & Gene Editing Protein degradation / PROTAC Ask AI ↗

2026-11-06Frontiers in Pharmacology

Review assesses the safety limits and translational gaps of MCL-1 degradation strategies

A Frontiers in Pharmacology review compares direct MCL-1 inhibition with approaches that reduce its abundance, including transcriptional interventions and targeted degradation. The original abstract highlights limited single-agent activity and cardiac safety concerns with inhibitors, while positioning degradation as an unvalidated clinical strategy. Biomarker-guided combinations and dynamic BH3 profiling are discussed; this review does not report a new clinical trial.

Protein degradation / PROTAC Ask AI ↗

2026-11-05C4 Therapeutics (GlobeNewswire)

C4 completes first cemsidomide–elranatamab safety-cohort enrollment and updates Phase 2 timeline

C4 Therapeutics reported completed enrollment of the first safety cohort in its Phase 1b cemsidomide–elranatamab combination trial. It expects Phase 2 MOMENTUM enrollment to finish in the first quarter of 2027, with initial response-rate data in the second half. At September 30, cash, cash equivalents and marketable securities totaled $274.7 million, with projected runway through 2028.

Companies mentionedC4 Therapeutics ↗

Protein degradation / PROTAC Ask AI ↗

Continue your research

All company profiles, filters, and comparisons are open. Sign in for private saves and member discussions.

Open full company map ↗